Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study

Tanya I. Coulter, MRCP, a,b Anita Chandra, PhD, FRCPath, a,c,d,e Chris M. Bacon, PhD, FRCPath, f,g James Curtis, PhD, h Nick Screaton, FRCP, FRCR, s John R. Goodlad, MD, FRCPath, s George Farmer, MD, h Cathal Laurence Steele, MB, f Timothy Ronan Leahy, MRCP, b Rainer Doffinger, PhD, FRCPath, c.i
Helen Baxendlex, PhD, FRCPath, i Jolanta Bernatoniene, PhD, k J. David M. Edgar, FRCP, FRCPath, l
Hilary J. Longhurst, PhD, FRCPath, m Stephan Eh, MD, PhD, m Carsten Speckmann, MD, m,n Bodo Grimbacher, MD, PhD, m,n Anna Sediva, MD, PhD, o Tomas Milota, MD, o Saul N. Faust, PhD, FRCPath, p,q Anthony P. Williams, PhD, FRCPath, p Grant Hayman, FRCP, FRCPath, r Zeynep Yesim Kucuk, MD, s Rosie Hague, MRCPI, FRCPath, s,u
Paul French, MD, MRC, DipFMS, FRCPath, s,u,v Richard Brooker, FRCPCH, t Peter Forsyth, FRCPPath, h
Richard Herriot, FRCP, FRCPath, t Caterina Cancrini, MD, PhD, t Paolo Palma, MD, PhD, t Paola Ariganello, MD, u
Niall Conlon, PhD, FRCPath, a Conleth Feighery, PhD, FRCPath, a Patrick J. Gavin, MD, t Alison Jones, PhD, FRCPath, y
Kohsuke Imai, MD, PhD, w,x Mohammad A. A. Ibrahim, PhD, FRCP, FRCPath, f,x Gasper Markelj, MD, x
Mario Abinun, MD, PhD, y,p Frédéric Rieux-Laucta, PhD, aa,bb, cc Sylvain Latour, PhD, aa, bb Isabelle Pellier, MD, PhD, d, ee, ff, gg
Alain Fischer, MD, PhD, aa, bb, cc, hh Fabien Touzot, MD, PhD, z, aa, bb Jean-Laurent Casanova, MD, PhD, aa, cc, ii, kk
Anne Durandy, MD, PhD, aa, bb, siobhan O. Burns, MD, PhD, t Sinisa Savic, PhD, FRCPath, mm
D. S. Kumaratne, FRCPath, Phil (Oxon), 6 Despina Moshous, MD, PhD, aa, cc Sven Kracker, PhD, aa, bb
Bart Vanhaesebroeck, PhD, FMedSci, nn Klaus Okkenhaug, PhD, o Capucine Picard, MD, PhD, aa, bb, cc, ee, ii, jj
Sergey Nejentsev, MD, PhD, o Alison M. Condiffe, PhD, FRCP, e, oo, a and Andrew James Cant, MD, FRCP, FRCPath pp, oo, a

Dublin, Ireland; Cambridge, Newcastle, Inverness, Belfast, Bristol, London, Southampton, Surrey, Aberdeen, Newcastle upon Tyne, Leeds, Sheffield, Glasgow, and Edinburgh, United Kingdom; Freiburg, Germany; Prague, Czech Republic; Cincinnati, Ohio; Rome, Italy; Ljubljana, Slovenia; Paris and Angers, France; New York, NY; Chevy Chase, Md; and Tokyo, Japan

Background: Activated phosphoinositide 3-kinase δ syndrome (APDS) is a recently described combined immunodeficiency resulting from gain-of-function mutations in PIK3CD, the gene encoding the catalytic subunit of phosphoinositide 3-kinase δ (PI3Kδ). Objective: We sought to review the clinical, immunologic, histopathologic, and radiologic features of APDS in a large genetically defined international cohort.

Methods: We applied a clinical questionnaire and performed review of medical notes, radiology, histopathology, and laboratory investigations of 53 patients with APDS. Results: Recurrent sinopulmonary infections (98%) and nonneoplastic lymphoproliferation (75%) were common, often from childhood. Other significant complications included herpesvirus infections (49%), autoinflammatory disease (34%),

From the Department of Immunology, School of Medicine, Trinity College, Dublin, and St James’s Hospital, Dublin; the Department of Paediatric Immunology and Infectious Diseases, Our Lady’s Children’s Hospital, Crumlin, Dubin; the Department of Clinical Biochemistry and Immunology, Addenbrooke’s Hospital, Cambridge; the Department of Medicine, University of Cambridge; the Northern Institute for Cancer Research, Newcastle University; the Department of Radiology, Cambridge University Hospitals NHS Foundation Trust; Raigmore Hospital, Inverness; the Regional Immunology Service, The Royal Hospitals, Belfast; the National Institute for Health Research, Cambridge Biomedical Research Centre; the Department of Infectious Disease and Immunology, University Hospitals Bristol NHS Foundation Trust, Bristol Royal Hospital for Children; the Center for Chronic Immunodeficiency, University Hospital Freiburg; the Department of Pediatrics and Adolescent Medicine, University Medical Center, Freiburg; the Institute of Immunology, University Hospital Motol, Prague; the Faculty of Medicine and Institute of Life Sciences, University of Southen; the National Institutes of Health Clinical Research Facility, University Hospital Southampton NHS Foundation Trust; the Department of Immunology, Epsom & St Helier University Hospitals NHS Trust, Surrey; the Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children’s Hospital Medical Center; the Department of Pediatrics, Ospedale Pediatrico Bambino Gesù and University of Rome “Tor Vergata,” Rome; the Department of Immunology, Great Ormond Street Hospital NHS Foundation Trust, London; King’s College London, King’s Health Partners, King’s College Hospital NHS Foundation Trust, School of Medicine, Division of Asthma, Allergy & Lung Biology, Department of Immunological Medicine, London; the Department of Allergology, Rheumatology and Clinical Immunology, University Children’s Hospital, University Medical Center, Ljubljana; the Department of Paediatric Immunology, Newcastle upon Tyne hospitals NHS Foundation Trust; the Department of Biotherapy, Centre d’Investigation Clinique intégré en Biothérapies, Necker Children’s Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris; Université Paris Descartes–Sorbonne Paris Cité, Institut Imagine, Paris; INSERM UMR1163, Paris; the Department of Pediatric Immunology, Hematology and Rheumatology, AP-HP, Necker Children’s Hospital, Paris; Unité d’Onco-hématologie-immunologie Pédiatrique, CHU Angers; Centre de Référence Déficits Immunitaires Héréditaires, AP-HP, Paris; INSERM UMR 892, Angers; CNRS UMR 6299, Angers; Collège de France, Paris; the Laboratory of Human Genetics of Infectious Diseases, Necker-Brancion, INSERM UMR1163, Imagine Institute, Necker Children’s Hospital, Paris; St Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York; Howard Hughes Medical Institute, Chevy Chase; University College London Institute of Immunity and Transplantation, London; the Department of Clinical Immunology and Allergy, St James’s University Hospital, Leeds; UCL Cancer Institute, University College London; the Department of Infection, Immunology and Cardiovascular Disease, University of Sheffield; the Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne Hospitals NHS Trust; Northern England Haemato-Oncology Diagnostic Service, Newcastle upon Tyne NHS Foundation Trust; Papworth Hospital NHS trust, Papworth Everard, Cambridge; the Department of Radiology, Papworth Hospital NHS Foundation Trust, Papworth Everard Hospital, Cambridge; the Department of Pathology, Western General Hospital, Edinburgh; the Department of Royal Hospital for Children, Glasgow; the Department of Pathology, Queen Elizabeth University Hospital, Glasgow; and the Department of Community Pediatrics, Perinatal and Maternal Medicine Tokyo Medical and Dental University (TMDU), Tokyo.

These authors contributed equally to this work.
and lymphoma (13%). Unexpectedly, neurodevelopmental delay occurred in 19% of the cohort, suggesting a role for P13Kδ in the central nervous system; consistent with this, P13Kδ is broadly expressed in the developing murine central nervous system. Thoracic imaging revealed high rates of mosaic attenuation (90%) and bronchiectasis (60%). Increased IgM levels (78%), IgG deficiency (43%), and CD4 lymphopenia (84%) were significant immunologic features. No immunologic marker reliably predicted clinical severity, which ranged from asymptomatic to death in early childhood. The majority of patients received immunoglobulin replacement and antibiotic prophylaxis, and 5 patients underwent hematopoietic stem cell transplantation. Five patients died from complications of APDS. Conclusion: APDS is a combined immunodeficiency with multiple clinical manifestations, many with incomplete penetrance and others with variable expressivity. The severity of complications in some patients supports consideration of hematopoietic stem cell transplantation for severe childhood disease. Clinical trials of selective P13Kδ inhibitors offer new prospects for APDS treatment. (J Allergy Clin Immunol 2016;138:440-451.)

Key words: Activated phosphoinositide 3-kinase δ syndrome, p110δ-activating mutation causing senescent T cells, lymphadenopathy, and immunodeficiency, phosphoinositide 3-kinase δ, PIK3CD gene, bronchiectasis, immunodeficiency, hematopoietic stem cell transplantation, phosphoinositide 3-kinase inhibitor

Activated phosphoinositide 3-kinase δ syndrome (APDS) is an autosomal dominant primary immunodeficiency caused by gain-of-function (GOF) mutations in PIK3CD,1,2 which encodes the p110δ catalytic subunit of phosphoinositide 3-kinase δ (P13Kδ). P13Kδ, a class 1 P13K isoform generating phosphatidylinositol 3,4,5-trisphosphate, is a heterodimer comprising p110δ and a p85 family regulatory subunit. P13Kδ is expressed predominantly in leukocytes and plays an important role in their proliferation, survival, and activation.1-5

T.C. is supported by the National Children's Research Centre, Our Lady’s Children’s Hospital Crumlin, Dublin, Ireland. A.C. has a Wellcome Trust Postdoctoral Training Fellowship for Clinicians (103413/Z/13/Z). K.O. is supported by funding from BBBSRC, MRC, the Wellcome Trust, and GlaxoSmithKline. R.D. and D.S.K. are funded by National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre, Cambridge, United Kingdom. C.S. and S.E. are supported by the German Federal Ministry of Education and Research (BMBF) 01 EO 0803 grant to the Center of Chronic immunodeficiency and BMBF 01GM1111B grant to the PID-NET initiative. S.N.F. is supported in part by the Southampton UK NIHR Wellcome Trust Clinical Research Facility and NIHR Respiratory Biomedical Research Unit. M.A.A.L. is funded by NHS Innovation London and King’s College Hospital Charitable Trust. A.F., S.L., A.D.-F., R.-L. and S.K. are supported by the European Union’s 7th RTD Framework Programme (ERC advanced grant PID-IMMUNE contract 249816) and a government grant managed by the French Agence Nationale de la Recherche as part of the “Investments for the Future” program (ANR-10-IAHU-01). S.L. is supported by the Agence Nationale de la Recherche (ANR) (ANR-14-CE14-0028-01), the Foundation ARC pour la Recherche sur le Cancer (France), the Rare Diseases Foundation (France), and the François Aupetit Association (France). S.L. is a senior scientist and S.K is a researcher at the Centre National de la Recherche Scientifique-CNRS (France). A.D. and S.K. are supported by the “Institut National de la Santé et de la Recherche Médicale.” S.K. is supported by the Fondation pour la Recherche Médicale (grant no. ING20130526624). A. Ligue Contre le Cancer (Comité de Paris), and Centre de Références des Déficits Immunitaires Heréditaires (CEREDIH). S.O.B. is supported by the Higher Education Funding Council for England. B.V. is supported by the UK Biotechnology and Biological Sciences Research Council [BB/F007806/1]. Cancer Research UK (C23338/A15965), and the NIHR University College London Hospitals Biomedical Research Centre. B.V. is consultant to Karus Therapeutics (Oxford, United Kingdom). S.N. is a Wellcome Trust Senior Research Fellow in Basic Biomedical Science (095198/Z/10/Z). S.N. is also supported by the European Research Council Starting grant 260477, the EU FP7 collaborative grant 261441 (PEVNET project), and the NIHR Cambridge Biomedical Research Centre, UK. A.M.C. is funded by the Medical Research Council (MR/M012328/1), British Lung Foundation, University of Sheffield, and Cambridge NIHR-BRC. Research in A.M.C.’s laboratory has received noncommercial grant support from GlaxoSmithKline, Novartis, and MedImmune.

Disclosure of potential conflict of interest: T. I. Coulter declares a grant from the National Children’s Research Centre, D8, Dublin and receiving travel funds from Baxter Healthcare, Dublin, Ireland. A. Chandra declares grants/grants pending from Wellcome Trust and GSK, being employed by Cambridge University, and travel funds from Shire. T. R. Leathy declares receiving funding for travel from Baxter and Fannin healthcare. J. H. Longhurst declares grants/grants pending from CSL Behring, Grifols, and Octapharma; providing consultancy to CSL Behring; receiving payment for lectures from CSL Behring, Baxalta, and Biotest; and receiving funds for travel/meeting expenses. H. Baxendale declares being employed as an NHS consultant, being a lecturer at Kings College, and receiving travel funds from Octapharma. J. M. Edgar declares providing consultancy to and receiving travel funds from CSL, Shire, and Baxter. S. Ehl declares grants/grants pending from German Ministry for Education and Research and UCB; providing consultancy to Novartis and UCB, and payments for lectures from Baxter. B. Grimbacher declares receiving grants/grants pending from BMBF, EU, Helmholtz, DFG, DLK, and DZIF; being employed by UCL and UKL-FR; and receiving payments for lectures from CSL Behring, Baxalta, and Biotest. A. Sedaiva declares receiving travel support from Novartis. R. Hague declares providing expert testimony for Baxter licensing, payment for lectures from Thermo Fisher, and travel funds from Wyeth and Zanofi Pasteur. N. Condon declares payment for lectures from Baxalta, Novartis, and GlaxoSmithKline and receiving travel funds from Baxalta. A. Jones declares providing consultancy to Sub-clinical infection Advisory Board for CSL-Behring, payment for lectures from CSL-Behring and LFB, and travel funds from CSL-Behring. K. Inami declares providing consultancy for, receiving a grant from, and receiving payments for lectures from CSL-Behring and receiving payments for lectures from Japan Blood Products Organization. M. A. A. Ibrahim declares providing consultancy to Biotest and receiving travel funds from BAXALTA. S. N. Faust declares providing consultancy to Astra Zeneca and Cubist and receiving grants/grants pending from Pfizer, Sanofi, GlaxoSmithKline, Novartis, Ailios, Regeneron, and Astra Zeneca. F. Touzet declares grants/pending grants from the European Research Council, European Union, and the Fondation pour la recherche médicale. D. S. Kumararatne declares a grant from National Institute of Health Research of UK; providing consultancy to Novartis, GlaxoSmithKline, and Shire; being employed by Addenbrookes Hospital Cambridge; providing expert testimony to Medicod-legal reports; receiving payment for lectures from Biotest; and receiving travel funds from UK the Primary Immunodeficiency association and CSL Behring. S. Kracker declares grants from ERC advanced grant PID-IMMUNE, Fondation pour la Recherche Médicale, the Ligue Contre le Cancer (Comité de Paris), Centre de Références des Déficits Immunitaires Heréditaires (CEREDIH), French Agence Nationale de la Recherche as part of the “Investments for the Future,” French Agence Nationale de la Recherche, and Fondation ARC pour la recherche sur le cancer and travel funds from Novartis Institutes for Biomedical Research. J.-L. Casanova declares providing consultancy to Genentech, Sanofi, Novartis, Pfizer, Bioaster, and Regeneron; grants/grants pending from Merck Sharpe & Dohme and Biegen Idec; and funds from ADA. S. O. Burns declares grants/grants pending from HEFCE, EU, NIH, GOSH/UCH BRC, and UCLH III BRC; consulting fees from CSL Behring; being employed by UCL; and receiving travel funds from Immunodeficiency Canada/IAACI, CSL Behring, and Baxalta US. B. Vanhaesebroeck declares grants from the Ludwig Institute for Cancer Research and BBSRC UK and being a board member and providing consultancy to Karus Therapeutics, Oxford UK. A. Neijentsev declares grants/pending grants from MRC and GlaxoSmithKline. A. M. Condliffe declares grants/grants pending from Medical Research Council, GlaxoSmithKline, and ESID and receiving travel funds from Keystone Symposia. A. J. Cant declares providing consultancy to LFB Biomedicaments. The rest of the authors declare that they have no relevant conflicts of interest.

Received for publication August 1, 2015; revised May 2, 2016; accepted for publication June 3, 2016.

Corresponding author: Allison M. Condliffe, PhD, FRCP, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom S10 2RX. E-mail: a.m.condliffe@sheffield.ac.uk.

http://dx.doi.org/10.1016/j.jaci.2016.06.021
Recently, we described 17 patients with a combined immunodeficiency disorder caused by the heterozygous PIK3CD GOF mutation E1021K. Patients’ lymphocytes displayed increased basal and poststimulation phosphorylation of phosphatidylinositol 3,4,5-trisphosphate and enhanced downstream Akt–mammalian/mechanistic target of rapamycin signaling. This disorder was named APDS.1 Lucas et al2 independently reported 14 patients with a similar disease caused by E1021K and 2 other activating mutations in PIK3CD, designating it p110d-activating mutation disease caused by E1021K and 2 other activating mutations in PIK3CD, designating it p110δ-activating mutation–activating mutation. We aimed to confirm cohort of 53 patients, the largest to date. We confirmed cohort of 53 patients, the largest to date. We demonstrated a wide spectrum of clinical findings and complications and unexpectedly noted an increased frequency of neurodevelopmental manifestations. These findings will aid clinical decision making in the diagnosis and treatment of APDS and facilitate patient counseling.

**METHODS**

Informed consent was obtained from patients, parents, or both. The study conformed to the Declaration of Helsinki and all local ethical requirements. Mutations in PIK3CD were identified by means of Sanger sequencing.1 Only patients heterozygous for an APDS-associated GOF PIK3CD mutation were included. Twenty-five patients from this cohort have been included in previous reports,1,7 and 28 are reported for the first time. Informed consent was obtained from patients, parents, or both. The study conformed to the Declaration of Helsinki and all local ethical requirements. Mutations in PIK3CD were identified by means of Sanger sequencing. Only patients heterozygous for an APDS-associated GOF PIK3CD mutation were included. Twenty-five patients from this cohort have been included in previous reports, and 28 are reported for the first time.

Information on demographics, presentation, complications, laboratory parameters, management, and outcomes was compiled retrospectively by using patient/parent interview and medical note review. Pneumonia and bronchiectasis required radiologic confirmation. Chest computed tomographic (CT) scans from 31 patients were independently reviewed by 2 thoracic radiologists (J.B. and N.S.) for air-space opacity, atelectasis, nodules, bronchiectasis, mosaic attenuation, and lymphadenopathy. Available histopathology specimens (29 specimens from 11 patients) were reviewed by 2 hematopathologists (C.M.B. and J.R.G.). Patients’ most recent immunology results are described; postrituximab B-cell levels were excluded. All laboratory results were analyzed with reference to age-related normal ranges. A poor pneumococcal polysaccharide vaccine (PPV) response was defined as a less than 4-fold increase in antipneumococcal IgG titer at 4 to 6 weeks after PPV vaccination.

**RESULTS**

Patients’ characteristics

Fifty-three patients with APDS (34 male patients) from 30 unrelated families were included; 5 patients (4 male) were deceased. Living patients had a mean age of 17.2 years (age range, <1-65 years). Forty-two patients were of European descent, 4 were Afro-Caribbean, 3 were Middle Eastern, 2 were Indian, 1 was Chinese, and 1 was Japanese. Fifty patients were heterozygous for E1021K, and 3 related subjects were heterozygous for E525K.

**Presentation**

Recurrent respiratory tract infections occurred in 96% of patients, with onset from less than 1 to 7 years of age. Lymphadenopathy, hepatosplenomegaly, or both were common infections described, with E1021K the most common.1,2,6-8 Patients in heterozygous for E1021K, and 3 related subjects were heterozygous for E525K. The disorder was named PIK3CD -activating mutation, designating it p110d-activating mutation disease caused by E1021K and 2 other activating mutations in PIK3CD, designating it p110δ-activating mutation–activating mutation. We aimed to confirm cohort of 53 patients, the largest to date. We demonstrated a wide spectrum of clinical findings and complications and unexpectedly noted an increased frequency of neurodevelopmental manifestations. These findings will aid clinical decision making in the diagnosis and treatment of APDS and facilitate patient counseling.

**METHODS**

Informed consent was obtained from patients, parents, or both. The study conformed to the Declaration of Helsinki and all local ethical requirements. Mutations in PIK3CD were identified by means of Sanger sequencing.1 Only patients heterozygous for an APDS-associated GOF PIK3CD mutation were included. Twenty-five patients from this cohort have been included in previous reports,1,7 and 28 are reported for the first time. Informed consent was obtained from patients, parents, or both. The study conformed to the Declaration of Helsinki and all local ethical requirements. Mutations in PIK3CD were identified by means of Sanger sequencing. Only patients heterozygous for an APDS-associated GOF PIK3CD mutation were included. Twenty-five patients from this cohort have been included in previous reports, and 28 are reported for the first time.

Information on demographics, presentation, complications, laboratory parameters, management, and outcomes was compiled retrospectively by using patient/parent interview and medical note review. Pneumonia and bronchiectasis required radiologic confirmation. Chest computed tomographic (CT) scans from 31 patients were independently reviewed by 2 thoracic radiologists (J.B. and N.S.) for air-space opacity, atelectasis, nodules, bronchiectasis, mosaic attenuation, and lymphadenopathy. Available histopathology specimens (29 specimens from 11 patients) were reviewed by 2 hematopathologists (C.M.B. and J.R.G.). Patients’ most recent immunology results are described; postrituximab B-cell levels were excluded. All laboratory results were analyzed with reference to age-related normal ranges. A poor pneumococcal polysaccharide vaccine (PPV) response was defined as a less than 4-fold increase in antipneumococcal IgG titer at 4 to 6 weeks after PPV vaccination.

**RESULTS**

Patients’ characteristics

Fifty-three patients with APDS (34 male patients) from 30 unrelated families were included; 5 patients (4 male) were deceased. Living patients had a mean age of 17.2 years (age range, <1-65 years). Forty-two patients were of European descent, 4 were Afro-Caribbean, 3 were Middle Eastern, 2 were Indian, 1 was Chinese, and 1 was Japanese. Fifty patients were heterozygous for E1021K, and 3 related subjects were heterozygous for E525K.

**Presentation**

Recurrent respiratory tract infections occurred in 96% of patients, with onset from less than 1 to 7 years of age. Lymphadenopathy, hepatosplenomegaly, or both were common

**TABLE I. Clinical manifestations of APDS**

<table>
<thead>
<tr>
<th>Frequency, n/total studied (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infections</td>
</tr>
<tr>
<td>Recurrent respiratory tract infections 51/53 (98)</td>
</tr>
<tr>
<td>Pneumonia† 39/46 (85)</td>
</tr>
<tr>
<td>Bronchiectasis‡ 32/53 (60)</td>
</tr>
<tr>
<td>Chronic rhinosinusitis 24/53 (45)</td>
</tr>
<tr>
<td>Recurrent otitis media (with permanent hearing loss) 26/53 (49)</td>
</tr>
<tr>
<td>Severe or persistent herpesvirus infection 26/53 (49)</td>
</tr>
<tr>
<td>EBV 14/53 (26)</td>
</tr>
<tr>
<td>CMV 8/53 (15)</td>
</tr>
<tr>
<td>HSV and VZV 11/53 (21)</td>
</tr>
<tr>
<td>Tonsillitis (with tonsillectomy) 7/53 (13)</td>
</tr>
<tr>
<td>Ocular infections 10/53 (19)</td>
</tr>
<tr>
<td>Noninfectious complication</td>
</tr>
<tr>
<td>Lymphadenopathy§ 34/53 (64)</td>
</tr>
<tr>
<td>Splenomegaly 31/53 (58)</td>
</tr>
<tr>
<td>Hepatomegaly 24/53 (45)</td>
</tr>
<tr>
<td>Autoimmune disease 22/53 (42)</td>
</tr>
<tr>
<td>Nodular mucosal lymphoid hyperplasia 17/53 (32)</td>
</tr>
<tr>
<td>Enteropathy¶ 13/53 (25)</td>
</tr>
<tr>
<td>Developmental delay 10/53 (19)</td>
</tr>
<tr>
<td>Lymphoma 7/53 (13)</td>
</tr>
</tbody>
</table>

Total studied = 53 unless otherwise indicated.

VZV: Varicella zoster virus.

*Pneumonia was defined as at least 1 clinically and radiologically diagnosed pneumonia episode.

†Bronchiectasis diagnosed on thoracic CT imaging.

‡Lymphadenopathy persistent for at least 3 months.

§Nine of 13 patients with enteropathy had gastrointestinal nodular mucosal lymphoid hyperplasia confirmed on endoscopy.

**Abbreviations used**

APDS: Activated phosphoinositide-3 kinase δ syndrome
BALF: Bronchoalveolar lavage fluid
CMV: Cytomegalovirus
CNS: Central nervous system
CT: Computed tomography
GOF: Gain of function
HSCT: Hematopoietic stem cell transplantation
HSV: Herpes simplex virus
OR: Odds ratio
PI3K: Phosphoinositide 3-kinase
PPV: Pneumococcal polysaccharide vaccine
at presentation (42%). Five patients were identified in adulthood after their child received a diagnosis of APDS; 2 had bronchiectasis and recurrent respiratory tract infections, 1 experienced recurrent respiratory tract infections in childhood and a persistent granulomatous local skin reaction to BCG vaccination, and 1 was under investigation for chronic cervical lymphadenopathy, and 1 had no reported health issues. The 4 symptomatic adults had abnormal immunoglobulin profiles, including increased IgM and reduced IgG₂ levels, although none had a low total IgG level.

Infective complications

Pneumonia (85%), bronchiectasis (60%), and upper respiratory tract infections were common, often with childhood onset (Table 1). Only 2 patients did not report recurrent respiratory tract infections. The most common bacterial pathogens were *Streptococcus pneumoniae* and *Haemophilus influenzae*, with *Staphylococcus aureus*, *Moraxella catarrhalis*, *Pseudomonas aeruginosa*, and *Klebsiella* species also observed. The mean age at diagnosis of bronchiectasis was 8.6 years (range, 1.3-36 years). Four patients had permanent hearing loss from recurrent otitis media. Non–respiratory tract bacterial infections included ocular infections (21%; conjunctivitis [n = 8], dacryocystitis [n = 3], and orbital cellulitis [n = 2]) and abscesses (17%; *S aureus* skin abscesses [n = 4], salivary gland abscesses [n = 3], dental abscesses [n = 3], and *S pneumoniae* lymph node abscess [n = 1]). No invasive bacterial infections were reported. Two unrelated patients had persistent granulomatous skin lesions at BCG vaccination injection sites (Fig 1); material from 1 lesion was culture positive for BCG. No other mycobacterial infections were reported.

Persistent, severe, or recurrent herpesvirus infections occurred in 49% of patients. EBV viremia was detected in 26%, with 6 (11%) patients having disseminated infection, including 1 case of EBV encephalitis. EBV was detected in lymph node (n = 3), tonsillar (n = 1), palatal (n = 1), and gastrointestinal (n = 1) biopsy specimens, as well as cerebrospinal fluid (n = 1) and bronchoalveolar lavage fluid (BALF; n = 1). Two patients had EBV-positive lymphoma. Eight patients had cytomegalovirus (CMV) viremia, 4 with systemic CMV infection successfully treated with ganciclovir. Four cases of EBV/CMV coinfection occurred. One patient with diffuse lymphadenopathy and hepatosplenomegaly had EBV, CMV, and human herpesvirus 6 identified by using PCR on lymph node biopsy. Two patients were hospitalized with severe primary varicella zoster virus infection, and 2 had recurrent shingles. A nongenotyped sibling reportedly died of varicella zoster virus pneumonitis at age 11 years. Recurrent herpes simplex virus (HSV) infections included oral ulceration (n = 4), skin infections (n = 2), and herpetic keratitis (n = 1). HSV was identified in BALF of 2 symptomatic patients, 1 with severe pneumonitis. Adenovirus infections were reported in 9 (17%) patients, with positive isolates from blood, BALF, and stool. Warts (n = 4) and *Molluscum contagiosum* (n = 4) were extensive in those affected.

*Cryptosporidium parvum* was isolated from a patient with bloody diarrhea at age 6 to 18 months in whom cirrhosis was identified at age 8 years; the liver biopsy specimen was negative for *Cryptosporidium* species. A second patient had *C parvum*-positive diarrhea immediately after hematopoietic stem cell transplantation (HSCT). The only other parasitic infection identified was toxoplasmosis in a 9-month-old child. Oral mucocutaneous candidiasis requiring treatment was reported in 7 (13%) patients, including candida tracheitis (n = 1) and esophageal candidiasis (n = 1). No cases of *Aspergillus* species infection were identified.

Noninfective immune complications

**Nonneoplastic lymphoproliferation.** Chronic lymphadenopathy, splenomegaly, and/or hepatomegaly were observed in 75% of patients (Table 1). Lymphadenopathy typically began in childhood, was persistent or recurrent, and was often localized to sites of infection. There were 14 cases of cervical lymphadenopathy; 8 of 10 patients with persistent intrathoracic lymphadenopathy had bronchiectasis and recurrent consolidation. Seven patients had diffuse lymphadenopathy, and EBV, CMV, or dual viremia was diagnosed in all 6 of these patients in whom viral PCR was performed. Lymphadenopathy was significantly associated with mucosal lymphoid hyperplasia (OR, 16; 95% CI, 1.9-133.8; *P* = .002), splenomegaly (OR, 9.1; 95% CI, 2.5-33.2; *P* = .005), and herpesvirus infection (OR, 6.9; 95% CI, 1.9-25.2; *P* = .004).

Histologically (Fig 2), lymph nodes showed atypical follicular hyperplasia with absent or attenuated follicular mantle zones. Germinal centers were frequently disrupted and partially effaced by numerous T cells, many of which were programmed cell death protein 1 (PD1)⁺, CD57⁺, or both, which is consistent with follicular Tₐₘ cells. Parasinusoidal aggregates of monocytes B cells were a recurrent feature. IgG⁺ plasma cells were reduced in number. One lymph node showed features analogous to those of posttransplantation lymphoproliferative disorder, which is characterized by a polymorphic infiltrate of B cells, T cells, epithelioid macrophages, and light chain–restricted plasma cells; monocytoid B-cell hyperplasia; and equivocal immunoglobulin gene rearrangement assays. There was no progression to lymphoma on prolonged follow-up. Scattered EBV-positive cells, CMV-positive cells, or both were present in several lymph nodes, but florid infectious mononucleosis-like pathology was not encountered. Mucosal nodular lymphoid
hyperplasia was visualized as cobblestone-like plaques or polyps in 17 (32%) patients. In the gastrointestinal tract mucosal lymphoid hyperplasia was identified endoscopically anywhere from the epiglottis to the rectum in 14 (26%) subjects and associated with diarrhea, bleeding, and rectal prolapse. Five patients had respiratory mucosal nodular lymphoid hyperplasia identified bronchoscopically (Fig 2). Biopsy specimens from mucosal lymphoid lesions showed follicular hyperplasia, often with features similar to those seen in lymph nodes (Fig 2), and were occasionally PCR positive for herpes viruses (EBV, n = 1; HSV, n = 1).

**Autoimmune and inflammatory disease.** Thirty-four percent of the cohort had clinical features suggestive of autoimmune or inflammatory disease. Cytopenias included Coombs-positive hemolytic anemia (n = 7) and 2 cases of trilineage cytopenia responsive to steroids or rituximab. Glomerulonephritis affected 3 children, necessitating renal transplantation in 2 cases.

**FIG 2.** Lymphoid hyperplasia. 1 and 2. Lymph node showing atypical follicular hyperplasia with disrupted follicles (arrows) and monocytoid B cells (arrowheads). 3-5. Disrupted germinal centers were highlighted by staining for CD20 (Fig 2, 3 and 4) and Bcl6 (Fig 2, 5). 6 and 7. Follicles were infiltrated by T cells (Fig 2, 6), many of which expressed PD1, CD57, or both (Fig 2, 7). 8. IgM-positive plasma cells were present, but IgG-positive plasma cells were reduced or absent. 9. Several lymph nodes contained CMV or EBV (EBER). 10. Tracheal endoscopy showing mucosal nodules. 11 and 12. Lung showing peribronchiolar lymphoid hyperplasia (Fig 2, 11) with disrupted follicles (Fig 2, 12). H&E, Hematoxylin and eosin.
Renal biopsy specimens showed proliferative, membranoproliferative, and focal and segmental changes. Two patients had exocrine pancreatic insufficiency. Autoantibody-positive thyroid disease was diagnosed in 3 patients in adulthood. Two patients had seronegative arthritis, and 1 had recurrent pericarditis.

Three patients had cirrhosis, of whom 1 also had sclerosing cholangitis in the setting of previous Cryptosporidium species–related diarrhea. Sclerosing cholangitis additionally affected a second noncirrhotic patient who had no evidence of Cryptosporidium species infection. Thirteen (25%) patients had chronic diarrhea, 9 of whom had gastrointestinal nodular mucosal lymphoid hyperplasia confirmed on endoscopy.

**Lymphoma and other malignancy.** Seven (13%) patients had lymphoma at age 18 months to 27 years. There were 2 cases of diffuse large B-cell lymphoma, 1 EBV positive (see Fig E1 in this article’s Online Repository at www.jacionline.org) and 1 EBV negative. Single patients were reported as having nodular sclerosis classical Hodgkin lymphoma, nodal marginal zone lymphoma, and a lymphoplasmacytic lymphoma, the EBV status of which were unknown. An EBV-positive Hodgkin-type lymphoproliferative disorder was diagnosed in a child after renal transplantation. One child had a primary cutaneous anaplastic large cell lymphoma carrying t(6; 7) (p25; q23). This regressed from a 9 × 6–cm mass of tumor nodules to a 5 × 4–cm diameter flat erythematous plaque on 6 weeks of treatment with rapamycin (sirolimus, see Fig E2 in this article’s Online Repository at www.jacionline.org). Three patients died of lymphoma-related complications, including both patients with EBV-associated lymphoma. No other malignancies have been identified within our cohort to date.

**Neurological and other nonimmune features.** Global developmental or isolated speech delay were diagnosed against standard criteria by specialist pediatric services in 10 (19%) patients. Three further patients were treated for anxiety disorders, 1 with a diagnosis of autism, and 3 children were reviewed by psychological services for behavioral issues. Of note, PI3Kδ is strongly expressed in the mature and developing murine central nervous system (CNS; Fig 3).

Individual patients were born with macrocrania, unilateral hypoplastic kidney, and unilateral microphthalmia.

**Thoracic radiology**

Air-space opacity (Fig 4.1) was identified in 13 of 31 CT scans reviewed, and tree-in-bud opacities, bronchial wall thickening, or both were identified in 20 of 31 CT scans. Mosaic attenuation was present in 28 of 31 patients and classified as mild in 17, moderate in 7, and severe in 4 (Fig 4.2). Bronchiectasis was present in 21 of 31 scans, with an average of 3 lobes affected, and associated with atelectasis or lobar collapse in 12 patients. Sixteen patients had mediastinal lymphadenopathy, which was in a regional draining station to concurrent lobar consolidation in 4 instances. Follow-up imaging was available in 8 patients at a mean interval of 2.2 years. Four of the patients with air-space opacity, and regional lymphadenopathy showed resolution of presumed pneumonic changes but persistent volume loss, atelectasis, and development of bronchiectasis (Fig 4.1).

**Immunology laboratory results**

Lymphocyte immunophenotyping findings are summarized in Table II. Typical findings were reduced CD4 T-cell counts, increased CD8 T-cell counts of an effector/effector memory phenotype, and an expansion of transitional B cells. A history of herpesvirus infection was not associated with a deficiency in natural killer cells (P = .48), T H1 cells (P = .47), or cytotoxic T cells (P = .55). Serial B-cell counts (n = 19) suggest that patients’ B-cell levels decrease more quickly over time than in age-matched control subjects (Fig 5).

Immunoglobulin levels (Table III) were variable, with 43% of patients having reduced total IgG levels. Fifty-eight percent of patients with normal IgG levels had IgG2 subclass deficiency, and 89% who underwent testing exhibited a poor response to PPV. Reduced IgA (50%) and increased IgM (79%) levels were common. Two patients initially had marginally reduced IgM levels (age, 2 and 6 years), which over time became high (27 g/L) or normal (0.63 g/L), respectively. In 4 cases high IgM levels normalized after commencement of immunoglobulin replacement. One patient had a low IgG level after previous normal readings. Four patients with normal IgG and IgA levels responded poorly to PPV and had a previous diagnosis of specific antibody deficiency.
Treatment

**Anti-infection prophylaxis.** Sixty-two percent of the cohort currently receive and an additional 9% previously received antibiotic prophylaxis. Six (11%) patients are taking antiviral and 3 (6%) are taking antifungal prophylaxis.

**Immunoglobulin replacement.** Long-term immunoglobulin replacement was administered to 87% of the cohort, with reported benefit (reduction of infection) in the majority. In 3 patients aged 14 to 23 years, immunoglobulin replacement was switched to antibiotic prophylaxis (patient preference). The 7 patients who did not receive immunoglobulin replacement therapy included the 5 patients identified by genotyping relatives of patients with APDS.

**HSCT.** Five (9%) patients aged 5 to 14 years have undergone HSCT with medium- or reduced-intensity conditioning with a median follow-up after HSCT of 4.2 years (range, 1-14 years). Three transplantations (unrelated donors, one with 1A and 1B allelic mismatch) were successful, with minimal graft-versus-host disease, restoration of normal growth, and resolution of infection and nonneoplastic lymphoproliferation; chimerism in these patients ranged from 35% to 100%. A fourth procedure was complicated by poor engraftment (25% donor chimerism), resulting in long-term immunoglobulin therapy after transplantation. A fifth patient, who underwent splenectomy before transplantation, died of sepsis 2 years after HSCT.

**Immunosuppression.** Thirty percent of the cohort underwent at least 1 course of immunosuppressive therapy for lymphoproliferative, autoimmune, or inflammatory disease. Rituximab was of benefit in the management of autoimmune hemolytic anemia (n = 8) and nonneoplastic lymphoproliferation (n = 5) although often complicated by sustained B-cell lymphopenia. Six patients were treated with rapamycin; 5 experienced benefit, with a decrease in nonneoplastic or neoplastic lymphoproliferation, but therapy was stopped in the fifth patient because of side effects.

**Fatal outcomes**

Five patients with APDS died, 3 (aged 1, 19, and 27 years) from lymphoma, 1 (aged 14 years) from sepsis after splenectomy and HSCT, and 1 (aged 39 years) from respiratory failure and chronic lung infection. Additionally, infection-related deaths in childhood and early adult life (≤30 years old) were reported for 5 non-genotyped relatives of patients with APDS.
NK cells

beige-like anchor protein (LRBA) deficiency. Interestingly, 3 lymphocyte–associated antigen 4 (CTLA4) and LPS-responsive those of other primary immunodeficiencies, such as cytotoxic T cells or necessitating HSCT in childhood; the clinical features overlap those of other primary immunodeficiencies, such as cytotoxic T lymphocyte–associated antigen 4 (CTLA4) and LPS-responsive beige-like anchor protein (LRBA) deficiency. Interestingly, 3 lymphocyte–associated antigen 4 (CTLA4) and LPS-responsive beige-like anchor protein (LRBA) deficiency. Interestingly, 3 lymphocyte–associated antigen 4 (CTLA4) and LPS-responsive beige-like anchor protein (LRBA) deficiency.

**DISCUSSION**

We present an overview of the clinical course of APDS in the largest cohort to date with confirmed GOF PIK3CD mutations. The phenotype is highly variable (Fig 6), ranging from asymptomatic adults to profound immunodeficiency causing early death or necessitating HSCT in childhood; the clinical features overlap those of other primary immunodeficiencies, such as cytotoxic T lymphocyte–associated antigen 4 (CTLA4) and LPS-responsive beige-like anchor protein (LRBA) deficiency. Interestingly, 3 recent publications describe heterozygous mutations in the PIK3R1 gene (encoding the PI3K regulatory subunit), leading to hyperactivation of PI3K

**TABLE II.** Summary of lymphocyte phenotypic characteristics of APDS

<table>
<thead>
<tr>
<th>Lymphocyte subpopulation*</th>
<th>Frequency, n/total studied (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>T cells</td>
<td></td>
</tr>
<tr>
<td>Reduced T_H cell counts (CD3 + CD4 + )</td>
<td>43/51 (84)</td>
</tr>
<tr>
<td>Reduced recent thymic emigrant T-cell counts</td>
<td>14/22 (64)</td>
</tr>
<tr>
<td>Normal cytotoxic T-cell counts (CD3 + CD8 + )</td>
<td>34/51 (67)</td>
</tr>
<tr>
<td>Reduced cytotoxic T-cell counts (CD3 + CD8 + )</td>
<td>14/51 (27)</td>
</tr>
<tr>
<td>Increased effector-effector memory cytotoxic T-cell counts (CD3 + CD8 + CD45RA + )</td>
<td>17/18 (94)</td>
</tr>
<tr>
<td>Reversed CD4/CD8 ratio</td>
<td>33/51 (65)</td>
</tr>
<tr>
<td>B cells</td>
<td></td>
</tr>
<tr>
<td>Reduced B-cell counts (CD19 + )</td>
<td>32/48 (67)</td>
</tr>
<tr>
<td>Increased transitional B-cell counts (CD19 + IgM + CD38 + )</td>
<td>24/32 (75)</td>
</tr>
<tr>
<td>Reduced nonswitched memory B cells (CD19 + IgD + CD27 + )</td>
<td>15/30 (50)</td>
</tr>
<tr>
<td>Reduced class-switched memory B-cell counts (CD19 + IgD + CD27 + )</td>
<td>17/30 (57)</td>
</tr>
<tr>
<td>NK cells</td>
<td></td>
</tr>
<tr>
<td>Normal NK cell counts (CD16 + CD56 + )</td>
<td>28/43 (65)</td>
</tr>
<tr>
<td>Reduced NK cell counts (CD16 + CD56 + )</td>
<td>12/43 (28)</td>
</tr>
</tbody>
</table>

NK. Natural killer.

*Results were deemed reduced, normal, or increased with reference to age-related normal ranges. Most recent results available were used, and B-cell levels after rituximab were excluded.

normal CD40 ligand expression, should be screened for activating PI3K \(\delta\) mutations.

Almost half of our cohort had difficulty in resolving herpes-virus infections, particularly EBV and CMV. Although APDS can present as a common variable immune deficiency–like disease, it is also characterized by viral infections; lymphocyte immunophenotyping confirms APDS is a combined immunodeficiency. The typical T-cell profile was of reduced T_H cells and recent thymic emigrants, whereas cytotoxic T cells had a predominantly effector or activated phenotype.

**TABLE III.** Summary of immunoglobulin characteristics of the APDS cohort

<table>
<thead>
<tr>
<th></th>
<th>Reduced, n/total (%)</th>
<th>Normal, n/total (%)</th>
<th>Increased, n/total (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IgG</td>
<td>21/49 (43)</td>
<td>26/49 (53)</td>
<td>2/49 (4)</td>
</tr>
<tr>
<td>IgA</td>
<td>25/50 (50)</td>
<td>24/50 (48)</td>
<td>1/50 (0.5)</td>
</tr>
<tr>
<td>IgM</td>
<td>0/50 (0)</td>
<td>12/50 (24)</td>
<td>38/50 (76)</td>
</tr>
<tr>
<td>Pneumococcal vaccine response*</td>
<td>25/28 (89)</td>
<td>3/28 (11)</td>
<td></td>
</tr>
</tbody>
</table>

Immunoglobulin results were deemed reduced, normal, or increased with reference to age-related normal ranges.

* A poor pneumococcal polysaccharide vaccine response was defined as less than 4-fold increase in anti-pneumococcal IgG titer at 4 to 6 weeks after PPV vaccination. Of the 25 patients in whom pneumococcal responses were not available, 15 had reduced IgG levels and received immunoglobulin replacement therapy.
B-cell numbers were often normal in early life but decreased with time. The reduction in B-cell counts, including class-switched memory B cells and expansion of transitional B cells, suggests defects in B-cell maturation or enhanced mature B-cell death.22

The development of focal bronchiectasis observed after consolidative therapies suggests the suspected causal link between infection and airway damage. Consistent with a role for infection in the florid nonneoplastic lymphoproliferation characteristic of patients with APDS, lymphadenopathy was often associated with regional (mediastinal lymphadenopathy in bronchiectatic patients) or systemic infection (herpesviral infections) and tended to improve on infection resolution. Our review of chest CT scans revealed an unexpectedly high incidence (28/31) of mosaic attenuation, which is indicative of reduced perfusion of poorly ventilated lung regions. This might reflect inflammatory small-airway disease or result from viral respiratory tract infections.

Patients with APDS had a high incidence (34%) and wide range of inflammatory/autoimmune manifestations. Enhanced PI3Kδ activity has been reported in patients with autoimmune diseases, such as systemic lupus erythematosus,28 and PI3Kδ modulates regulatory T-cell function.29 Our findings suggest a role for PI3Kδ in the genesis or perpetuation of autoimmunity and potentially for PI3Kδ inhibition in treating such conditions. Activating somatic PIK3CD mutations have been associated with lymphoid malignancy.30 We identified 7 lymphomas in this series of 53 patients with a spectrum of pathologic subtypes but identified no solid malignancies, perhaps reflecting the young age of our cohort or the predominant expression of p110δ in leukocytes. Although PI3Kδ is described as leukocyte restricted, expression is also found in cells of breast or melanocytic origin,31 lung fibroblasts,32 and TNF-α-stimulated endothelial and synovial cells.33 p110δ has recently been shown to regulate epithelial cell polarity,34 which is of potential import for respiratory epithelial function. It is tempting to speculate that induction of p110δ expression by locally produced TNF-α during inflammation might impair epithelial barrier functions and aggravate local inflammation. Thus the lung phenotype might be the result of interplay between immune functions of p110δ and epithelium-intrinsic roles of p110δ.

Almost one fifth of our cohort experienced neurodevelopmental morbidity, from speech delay to global developmental delay. PI3Kδ is expressed broadly in the developing CNS, as well as in specific adult brain regions (including the hippocampus, cerebral cortex, and thalamus) of reporter mice (Fig 3).16 PI3Kδ has been implicated in schizophrenia; pharmacologic inhibition reversed prepulse inhibition deficits in a rat model of schizophrenia and blocked amphetamine-induced hyperlocomotion in a mouse model of psychosis-like behavior.35 Interestingly, loss-offunction phosphatase and tensin homolog (PTEN) mutations (with consequent enhanced PI3K-dependent signaling) are associated with macrocrania and autism spectrum disorders.36 One patient with APDS had macrocrania, and in addition to the single patient with a formal diagnosis of autism in our cohort, before submission of this manuscript, we were informed of an additional patient with APDS with autism spectrum disorder (personal communication; Professor P. Martin von Hagen, Erasmus MC, The Netherlands). These findings suggest PI3Kδ might play an important but little-understood role in the CNS, and this aspect of APDS warrants further study.

HSCT has been seemingly curative in 3 patients with APDS described herein and an additional 5 patients described by Imai et al,37 supporting its use in carefully selected cases; however, longer-term follow-up to determine the degree of donor chimerism needed to achieve cure is required. Lucas et al2 reported a single patient in whom the mammalian/mechanistic target of rapamycin inhibitor rapamycin improved circulating T-cell profiles. Four patients within our cohort experienced a decrease in nonneoplastic lymphoproliferation while taking rapamycin, and this drug also led to regression of cutaneous T-cell lymphoma. Nevertheless, direct inhibition of activated PI3Kδ might be a more attractive approach in patients with APDS. Selective PI3Kδ inhibitors are currently in clinical trials for a range of cancers and inflammatory disorders, and one compound is already approved for treatment of B-cell malignancies.38,39 Such disease-specific therapy could address both the infectious and noninfectious complications of APDS, but the reported side effect profile and significant immunoparesis in mice lacking PI3Kδ function25 emphasize the need for careful dosing to restore normal rather than abolish PI3Kδ activity, particularly given that long-term treatment is contemplated.

In conclusion, APDS is a combined immune deficiency with a variable phenotype complicated by recurrent sinopulmonary bacterial and herpesvirus infections, bronchiectasis, lymphoid hyperplasia, autoimmunity, and, less frequently, neurodevelopmental delay and lymphoma. The rapidly increasing number of patients identified since the initial description of APDS in 2013 suggests this is a clinically significant cause of primary immunodeficiencies, which should be considered in patients presenting with atypical or inherited primary antibody deficiency, bronchiectasis, severe herpesvirus infections, and lymphoma. The severity of complications and significant mortality rate support
the consideration of HSCT in young patients, as well as clinical trials of selective PI3Kδ inhibitors for this condition.

We thank Erwan Dumontet, Marie-Céline Deau, and Rémy Rodriguez for technical support and Dr Hideki Sano for his contribution.

**Clinical implications:** The variable clinical phenotype with severe complications of bronchiectasis, bacterial and viral infections, and lymphoma suggests that patients who fit this clinical profile should be screened for APDS-causing mutations.

**REFERENCES**


REFERENCES
FIG E1. EBV-positive diffuse large B-cell lymphoma in patients with APDS. 1. A diffuse infiltrate of large atypical lymphoid cells and some atypical plasmacytoid cells was present in the cerebellum. 2. Immunohistochemical staining showed large B cells expressing CD20, CD79a, Pax5, and interferon regulatory factor 4 but not Bcl6 or CD10. 3. Most neoplastic cells showed positive in situ hybridization for EBV EBER. 4. Plasmacytoid cells expressed CD138 and showed λ restricted immunoglobulin light chain in situ hybridization. H&E, Hematoxylin and eosin.
FIG E2. Primary cutaneous anaplastic large cell lymphoma in patients with APDS. 1 and 2, A multinodular cutaneous tumor on the chest of an 11-year-old boy (Fig E2, 1), which regressed to a flat plaque (Fig E2, 2) on 6 weeks of treatment with rapamycin. 3 and 4, The dermis and subcutis contained a diffuse infiltrate of large atypical lymphoid cells. 5 and 6, Immunohistochemical staining showed large T cells expressing CD3 (Fig E2, 5), CD30 (Fig E2, 6), CD2, interferon regulatory factor 4, T-cell receptor β, and perforin but not CD4, CD8, or ALK. H&E, Hematoxylin and eosin.
### TABLE E1. Comparison of the frequency of complications in patients with APDS and common variable immune deficiency

<table>
<thead>
<tr>
<th>Clinical feature</th>
<th>Frequency (%) in APDS cohort</th>
<th>Frequency (%) in CVID cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pneumonia</td>
<td>85</td>
<td>32-77&lt;sup&gt;1,4&lt;/sup&gt;</td>
</tr>
<tr>
<td>Bronchiectasis</td>
<td>60</td>
<td>23-64&lt;sup&gt;1,3,5-7&lt;/sup&gt;</td>
</tr>
<tr>
<td>Splenomegaly</td>
<td>58</td>
<td>15-30&lt;sup&gt;1,3-6&lt;/sup&gt;</td>
</tr>
<tr>
<td>Autoimmunity</td>
<td>42</td>
<td>22-29&lt;sup&gt;1,3&lt;/sup&gt;</td>
</tr>
<tr>
<td>Enteropathy</td>
<td>25</td>
<td>9&lt;sup&gt;1,4,5&lt;/sup&gt;</td>
</tr>
<tr>
<td>Granuloma&lt;sup&gt;*&lt;/sup&gt;</td>
<td>0</td>
<td>8-9&lt;sup&gt;1,2,5&lt;/sup&gt;</td>
</tr>
<tr>
<td>Meningitis/encephalitis</td>
<td>1.9</td>
<td>3-4&lt;sup&gt;1,4&lt;/sup&gt;</td>
</tr>
<tr>
<td>Lymphoma</td>
<td>11</td>
<td>3-8&lt;sup&gt;1,2,5&lt;/sup&gt;</td>
</tr>
<tr>
<td>Living patients currently</td>
<td>77</td>
<td>80&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td>receiving immunoglobulin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>replacement therapy</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CVID, Common variable immune deficiency.

<sup>*</sup>Two patients with cutaneous granulomatous inflammation after BCG vaccination were not included.